Company intelligence / Profile preview

mAbxience

León, León, Spain

Ownership: Private
Development stage: Commercial

Overview

mAbxience has developed and commercialized two biosimilar medicines in oncology—rituximab and bevacizumab—available globally. The company maintains a robust pipeline targeting oncology, hematology, osteoporosis, pediatrics, and rare diseases like Fabry disease through partnerships. Their products meet stringent global regulatory standards.

Therapeutic areas: ImmunologyEndocrinologyHematologyOtherOncologyRare Diseases
Modalities: Monoclonal antibodies (mAbs)BiosimilarsOther biologics
Industry: Biotech

Drug pipeline

4 assets

palivizumab biosimilar MB05

3 more assets in the full pipeline.

Request access →

Partnerships

Over thirty global/regional partners for B2B commercialization/distribution worldwide.Strategic manufacturing agreement with Biosidus for Agalsidase Beta/Fabrazyme biosimilar production.

Beyond the preview

Go deeper on mAbxience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mAbxience.

Explore the full profile